Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan's common stock began trading on the Nasdaq Global Market on June 18, 2026, under ticker KARD, with the offering expected to close on June 22, 2026.
Kardigan
Private
Kardigan is a clinical-stage cardiovascular biotechnology company founded by Tassos Gianakakos, the former CEO of MyoKardia (acquired by Bristol-Myers Squibb for $13B), with a portfolio of in-licensed cardiovascular drug candidates targeting cardiomyopathies and related heart conditions.
Company Info
Sector:Biotechnology / Cardiovascular
Headquarters:South San Francisco, California, USA
Founded:2023
Website:www.kardigan.bio/
Funding Round:IPO filing June 2026 (~$320-369M planned)
Total Funding:$300M+ private financing prior to IPO
Funding & Investor Relations
Notable Investors
- Atlas Venture
- ARCH Venture Partners
- GV (Google Ventures)
- Perceptive Advisors
- Bain Capital Life Sciences
- Sequoia Heritage
IPO Outlook / Plans
Filed to raise $320M to $369M in a Nasdaq IPO in June 2026, with three in-licensed cardiovascular programs.
Upcoming Milestones & Key Dates
Q2 2026
Financing
Expected close of Nasdaq IPO at $320-369M
H2 2026
Clinical Trial
Phase 2 KARDIA-HCM interim data for KDG-101 in HCM
Clinical Development Pipeline
KDG-101 (formerly MYK-224 derivative)
Target: Cardiac myosin modulatorKDG-201
Target: Cardiac myosin activatorKDG-301
Target: Selective pulmonary vasodilatorRecent News
Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven track record
Kardigan, a cardiovascular-focused biotech founded in 2023 by former MyoKardia executives, filed for a Nasdaq IPO under ticker KARD, targeting $320 million (up to $369 million with greenshoe).
Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven track record
Kardigan, a cardiovascular-focused biotech founded in 2023 by former MyoKardia executives, filed for a Nasdaq IPO under ticker KARD, targeting $320 million (up to $369 million with greenshoe).
Kardigan Stitches Up $369M IPO Plan for Heart Drugs
Kardigan, the cardiology biotech led by a former MyoKardia executive, has filed to raise up to $369M in a US IPO to fund a pipeline of three in-licensed cardiovascular programs targeting cardiomyopathies and related heart conditions.
Leadership Team
Careers & Job Openings